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Background: The CD5 protein antagonizes phosphorylation events downstream of T cell receptor (TCR) engagement
to decrease T cell responsiveness. CD5-negative T cell clones respond preferentially over their CD5+ counterparts
against cells with low human histocompatibility-linked leukocyte antigen (HLA) levels. In human immunodeficiency
virus type 1 (HIV-1) infection, CD5−CD8+ T cells increase in prevalence with disease progression.
Methods: To investigate potential causes of this expansion of CD5−CD8+ T cells in HIV-1 infection, we compared CD5
expression on CD8+ T cells reactive against HIV-1 peptides, common viral peptides and a self peptide that together
span a broad range of TCR avidities in the context of the common HLA-A2 class I restriction molecule. Following
stimulation, CD5 expression on peptide-specific CD8+ T cells was assessed by flow cytometry.
Results: In healthy controls, there was no significant difference in the CD5+ percentage of CD8+ T cells specific for
common viral peptides, but a lower percentage of those responding against a common self peptide expressed CD5.
The same relationship occurred in HIV-infected individuals, however, a lower percentage of HIV peptide-specific CD8+
T cells than other viral peptide-specific CD8+ T cells expressed CD5. In terms of overall CD5 expression level at the
peptide-specific responder population level, HIV-specific CD8+ T cells resembled those responsive against the self
peptide, despite much higher avidity TCR/HLA/peptide interactions.
Conclusions: This deficit in CD5 expression selective for HIV-specific CD8+ T cells is consistent with in vivo adaptation
to low avidity HIV peptide variants and has potential consequences for CD8+ T cell expansion, cross-reactivity and
autoreactivity.
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Selective recognition of peptides within particular major
histocompatibility complex (MHC) molecules by clono-
typic T cell receptors (TCR) underlies both the specifi-
city and mechanics of T cell activation. While the overall
strength or avidity of the cognate TCR/peptide/MHC
interaction must itself exceed a certain threshold, non-
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unless otherwise stated.can modulate the tenor of signal transduction and sway
the outcome of antigen-specific recognition. The group
B cysteine-rich scavenger receptor CD5 modulates
antigen-specific signaling on virtually all T cells in a
ligand-independent manner [1-5]. When T cells form
conjugates with antigen-presenting cells, CD5 colocal-
izes with TCRs engaging cognate MHC/peptide com-
plexes within the immunological synapse and recruits
SHP phosphatases to the area through its cytoplasmic
tyrosine inhibitory motif (ITIM), [3,6]. Thus, localized
antagonism of phosphorylation events by CD5 dimin-
ishes TCR-derived activation signals [7]. With higher
levels of CD5, the interaction between TCR and MHC/Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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inhibition. This implies a relationship where the level of
CD5 expression on a T cell could fine tune the avidity of
cognate TCR/MHC/peptide complex interactions re-
quired for T cell activation [8].
The first direct evidence that CD5 represses T cell
activation was hyperresponsiveness of thymocytes from
CD5-knockout mice to TCR signaling, implicating
thymic selection in tuning CD5 expression levels to TCR
avidity [4,9]. As thymocytes mature, CD5 and TCR levels
increase in parallel, which should facilitate early positive
selection of CD5low thymocytes by lower avidity interac-
tions and hinder late negative selection of CD5high thymo-
cytes by higher avidity interactions [10]. The modulating
effect of CD5 during thymic selection and tuning of CD5
levels potentially extends the overall avidity range of the
selected TCR repertoire, especially at the higher end. In
TCR transgenic mice, autoreactive T cells with high levels
of CD5 expression escape negative thymic selection, but
peripheral downregulation of CD5 releases their autoreac-
tivity [11-13]. There is also a striking difference in vitro in
the behaviour of T cell clones derived from tumour-
infiltrating lymphocytes in that only CD5-negative clones
are activated by tumour cells expressing low levels of cog-
nate MHC/peptide complexes [14]. Since the clones have
identical TCR, CD5 expression is not inexorably hard-
wired to TCR avidity and under certain conditions, adapts
to the antigenic environment or to homeostatic pressures
to either increase or decrease T cell responsiveness
[15-17]. However, the role that CD5 expression plays in
shaping peripheral T cell responses against foreign anti-
gens in non-transgenic animals is completely obscure.
Substantial increases in CD5-negative T cells were re-
ported in human immunodeficiency virus type 1 (HIV-1)
infection, especially in its later stages [18]. These data
predate the introduction of highly active antiretroviral
therapy (HAART), suggesting a relationship between
robust HIV replication and selective expansion of CD5-
negative T cells. The CD5-negative T cells observed were
predominantly CD8+, but neither their specificity nor
function was investigated [18]. Subsequent studies of
CD8+ T cells in HIV infection have reported abnormal
promiscuity amongst HIV peptide-specific CD8+ T cells,
including unexpected cross-reactivity against multiple
HIV peptides, other viral peptides and self peptides
[19-21]. The high mutation rate of HIV generates mul-
tiple variants of the peptide epitopes activating HIV-
specific CD8+ T cells. While some are escape mutants,
many variants will bind the same class I MHC protein,
but mediate higher or lower avidity interactions with the
TCR of CD8+ T cells initially activated by the wild type
peptide. In this setting, downregulation of CD5 could
compensate for loss of avidity, selectively reduce the per-
centage of HIV-specific CD8+ T cells expressing CD5and increase the likelihood of CD8+ T cell cross-
reactivity and autoreactivity.
To investigate the possibility of selective reduction in
the percentage of HIV peptide-specific CD8+ T cells ex-
pressing CD5, we compared CD8+ T cells specific for HIV
peptides, non-HIV viral peptides, and a low avidity self
peptide in HIV-infected individuals and healthy controls.
Our rationale was that CD8+ T cells reactive against pep-
tides from viruses with much less variation than HIV
would not undergo selection for CD5-downregulation and
a higher percentage would express CD5. Dominant CD8+
T cell epitopes from common influenza (flu), cytomegalo-
virus (CMV) and Epstein-Barr virus (EBV) viruses were
selected for comparison with dominant CD8+ T cell epi-
topes from HIV and the common self peptide. We chose
these particular viruses and epitopes restricted to HLA-
A2 because widespread exposure of the general popula-
tion to flu, CMV and EBV and the high frequency of
HLA-A2 in the population make the comparison feasible
with less subject screening. Healthy controls expressing
HLA-A2 were initially screened by interferon-gamma
(IFN-γ) ELIspot assay for reactivity against the common
viral peptides and self peptide, while HIV-infected individ-
uals expressing HLA-A2 were screened against the com-
mon viral peptides, HIV peptides and common self
peptide. For those individuals reactive by ELIspot, we
followed up with CD8+ T cell proliferation assays, which
allowed us to assess by flow cytometry the percentage of
CD8+ T cells expressing CD5 in the population respond-
ing to the peptide. The percentage of CD8+ T cells
expressing CD5 varies with their specificity and with the
underlying avidity of TCR/peptide/MHC interactions.
Results
Percentage of circulating CD8+ T cells expressing CD5 in
HIV-infected and uninfected individuals
Before assessing the percentages of peptide-specific CD8+
T cells expressing CD5 in HIV-infected individuals and
healthy controls, we measured the percentage of CD8+ T
cells expressing CD5 in the general CD8+ T cell popula-
tions of 32 HIV-infected individuals and 17 healthy con-
trols by flow cytometry. The median percentage of CD8+
T cells expressing CD5 was significantly lower for the
HIV-infected individuals (median = 95.3, interquartile
range 93.5-96.6 versus median 98.6, interquartile range
97.1-99.5, p < 0.0001, Mann Whitney test). While HIV-
infection significantly reduces the proportion of CD8+ T
cells expressing CD5, a median of > 95% of all CD8+ T
cells expressed CD5 in both groups (Figure 1). Thus, in
the post-HAART era, with HIV replication effectively sup-
pressed, a small subset of CD8+ T cells is selectively
affected by HIV infection in terms of CD5 expression.
Subsequent experiments addressed the potential contribu-
tion of different CD8+ T cell specificities to this effect.
Figure 1 Comparison of the percentage of circulating CD8+
T cells expressing CD5 in HIV-infected individuals and healthy
controls. The median percentage of circulating CD8+ T cells
expressing CD5 measured by flow cytometry is shown for each
group by a horizontal line bisecting the data points with upper and
lower horizontal lines in each group indicating interquartile range.
Significant difference between the medians is indicated by the
p value above the line spanning the data sets (Mann–Whitney test).
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CD8+ T cells expressing CD5 in healthy controls
We first analyzed CD8+ T cells proliferating in response
to the common non-HIV viral peptides and IP-30 self-
peptide in HLA-A2+ healthy controls to test if a general
relationship between avidity of peptide/TCR interactions
and the percentage of responding CD8+ T cells express-
ing CD5 was apparent. Avidities of the non HIV and
HIV peptides used in this study are listed in Table 1.
The percentage of peptide-specific CD8+ T cells express-
ing CD5 was estimated by flow cytometry after gating
on CD8+CD3+ cells and visualizing CD5 expression on
CFSElow cells as shown for representative examples in
Figure 2. For the 3 foreign peptides, medians of 97.0%,
96.3% and 95.3% of CMV, EBV and flu peptide-specific
CD8+ T cells respectively, expressed CD5, with noTable 1 Selected peptides and corresponding avidities of
TCR/HLA-A2/peptide interaction
Peptide Protein and location Sequence Avidity
CMV pp65 495-503 NLVPMVATV 1.0 nM
Flu Matrix 55-63 GILGFVFTL 250 nM
EBV BMLF1 280-288 GLCTLVAML 500 nM
IP-30 IP-30 -11 to −3 LLDVPTAAV 2.0 μM
Gag p17 77-85 SLYNTVATL 50 nM
RT1 RT 33-41 ALVEICTEM 10 nM
RT2 RT 179-187 VIYQYMDDL 10 nM
PR PR 76-84 LVGPTPVNI 0.1 nMsignificant difference between medians (Figure 3a). Only
4 of 24 uninfected controls tested had CD8+ T cell pro-
liferation stimulated by the low avidity IP-30 self peptide,
with a median of 86.5% of the responding CD8+ T cells
expressing CD5. While the non-HIV viral peptides tested
varied from 1.0 to 500 nM in TCR avidity, the avidity
difference over this range was not reflected in signifi-
cantly different percentages of responding CD8+ T cells
expressing CD5. However, a significantly lower percent-
age of CD8+ T cells responding against the IP-30 self
peptide (avidity = 2.0 μM) expressed CD5 compared to
the CD8+ T cells responding against the highest avidity
CMV peptide (p < 0.02, Mann–Whitney test). The small
number of responses to the IP-30 peptide in the non-
HIV-infected population limited the significant differ-
ence to CMV-specific CD8+ T cells when individual
comparisons between peptide-specific CD8+ T cells were
done, but when grouped together, a significantly higher
percentage of the CMV, EBV and flu peptide-specific
CD8+ T cells expressed CD5 than the IP-30 peptide-
specific CD8+ T cells (p < 0.02, Mann–Whitney test).
These data indicate an increase in the percentage of
CD5-negative peptide-specific CD8+ T cells in associ-
ation with a low avidity TCR/peptide/MHC interaction
in non-HIV-infected healthy control subjects.
Percentage of CMV, EBV, flu and IP-30 peptide-specific
CD8+ T cells expressing CD5 in HIV infection
Data collected in the previous section allows us to test
whether the overall reduction in percentage of CD8+ T
cells expressing CD5 in HIV-infected individuals was
reflected in non-HIV peptide-specific CD8+ T cells. To
address this possibility, we next analyzed CD8+ T cells
responding to non-HIV viral peptides and the IP-30 self-
peptide in HIV-infected individuals. General characteris-
tics of the HIV-infected study subjects are listed in
Table 2. All subjects selected for testing were previously
identified as expressing HLA-A2. For the 3 foreign pep-
tides, medians of 98.4%, 97.6% and 96.7% of CMV, flu
and EBV peptide-specific CD8+ T cells respectively from
HIV-infected individuals expressed CD5, with no signifi-
cant differences between peptides (Figure 3b). The per-
centage of CD8+ T cells reacting against the IP-30 self
peptide that expressed CD5 (median = 88.4%) was sig-
nificantly less than the percentages of CD8+ T cells
reacting against the CMV, EBV and flu peptides either
individually (p = 0.0004, p < 0.02 and p = 0.004 respect-
ively, Mann–Whitney test) or grouped together (p =
0.0004, Mann–Whitney test). The percentages of CMV,
EBV, flu and IP-30 peptide-specific CD8+ T cells ex-
pressing CD5 were not significantly different between
the HIV-infected and healthy control groups, either
when compared individually or grouped together as
non-HIV viral peptide-specific CD8+ T cells. Therefore,
Figure 2 Assessment of the percentage of peptide-specific CD8+ T cells expressing CD5. Responder cells were labeled with CFSE, stimulated
with the desired peptides for 7 days, surface stained for CD3, CD8 and CD5 and then analyzed by flow cytometry. CD3+CD8+ lymphocytes were
positively gated from the live lymphocyte population (a) and the fraction of proliferating cells expressing CD5 was calculated by visualizing CFSE
fluorescence intensity versus CD5 in plots b-d. Proliferating, peptide responsive cells have lower CFSE fluorescence intensity than the parental non-
responding, non proliferating population (b). Numbers in the quadrants of plots (b-d) represent CD5+ (upper quadrants) and CD5-negative (lower
quadrants) percentages of the non-responding (right hand quadrants) and peptide responsive CD8+ T cell populations (left hand quadrants).
Representative examples where the percentage of peptide-responsive, proliferating cells not expressing CD5 spans a range of 1% (b) to 16% (d) are
shown for CD8+ T cell responses to the CMV (b) PR (c) and Gag (d) peptides described in Table 1.
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cific for non-HIV viral peptides in terms of the percent-
age expressing CD5. As in the uninfected group, an
increase in the percentage of CD5-negative T cells was
associated with a low avidity TCR/peptide/MHC inter-
action involving a self peptide relative to those CD8+ T
cells with higher avidity TCR/peptide/MHC interactions
involving non-HIV viral peptides.
Percentage of HIV peptide-specific CD8+ T cells
expressing CD5
Next, we analyzed CD5 expression on CD8+ T cells
responding to HIV peptides. The percentages expressing
CD5 were generally lower than for CD8+ T cells respond-
ing to non-HIV peptides and similar to the percentages ofCD8+ T cells reacting against the low avidity IP-30 self
peptide (Figure 4a). There was no significant difference in
the percentage of CD8+ T cells expressing CD5 between
the 4 HIV peptides themselves, nor between any of the 4
HIV peptides, individually or in aggregate, and the IP-30
self peptide. Since there was no significant difference be-
tween CD5 expression levels of the individual HIV
peptide-specific CD8+ T cell populations, we grouped
them together for comparison with the non-HIV viral pep-
tide and IP-30 peptide-specific CD8+ T cell populations of
the HIV-infected and uninfected groups. A significantly
lower percentage of HIV-specific CD8+ T cells expressed
CD5 compared to the non-HIV viral peptide specific
CD8+ T cells of HIV-infected (p = 0.0007, Mann–Whitney
test) and healthy control (p = 0.02, Mann–Whitney test)
Figure 3 Comparison of the percentage of non-HIV peptide-specific CD8+ T cells expressing CD5 for healthy controls and HIV-infected
individuals. Solid columns represent median values of the percentage of peptide-specific CD8+ T cells expressing CD5 for each individual
peptide (identified below the column) with error bars showing interquartile range for healthy controls (a) and HIV-infected individuals (b). The
number of individuals in each group with specific proliferation against each individual peptide is indicated by the n value within the column.
Significant differences between medians are shown by p values above lines bracketing the relevant groups (Mann–Whitney test).
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centage of HIV peptide-responsive CD8+ T cells ex-
pressing CD5 was greater than for the non-HIV viral
peptide-specific CD8+ T cells in either the HIV-infected or
uninfected group (Figure 4b). These data indicate a
broader range and selective reduction of the percentage
of CD8+ T cells expressing CD5 within the HIV-specific
CD8+ T cell population relative to the CD8+ T cells spe-
cific for other viral peptides in both the HIV-infected
and healthy control groups. Features of the HIV-specific
CD8+ T cells in terms of the range and median percent-
age expressing CD5 were similar to those of the self-
peptide reactive CD8+ T cells.
IP-30 self peptide reactivity
Since downregulation of CD5 on transgenic T cells is asso-
ciated with manifestation of autoreactivity, we compared
the frequency and levels of CD8+ T cell reactivity against
the IP-30 self peptide in healthy control and HIV-infected
study groups [14]. Proliferative CD8+ T cell responses
against the IP-30 self peptide occurred in both the healthy
control (4/24) and HIV-infected groups (13/36). There
was a trend towards more frequent IP-30 self-peptide
reactivity in HIV infection (p = 0.051, χ2 test) and several
individuals in the HIV-infected group had notably strong
proliferative responses to the IP-30 self peptide, but there
was no significant difference in the median percentage of
CFSElow cells between IP-30 peptide responders in the
HIV-infected versus healthy control groups (Figure 5).
Discussion
The role of CD5 as a negative regulator of TCR signaling
is well established and selective activation of variant
CD5-negative T cell clones by tumour cells expressinglow levels of HLA-class I/antigenic peptide complexes
illustrates its biological relevance [15]. While modulation
of CD5 under various conditions on transgenic T cells
and selective expansion of CD5-negative T cells in HIV
infection have been described, this is the first study com-
paring the percentage of CD5+ T cells from extended T
cell repertoires responding against different peptides
ranging in TCR avidity. The mean CD5-negative per-
centage of CD8+ T cells responding to three peptides
from common viruses was low (6% or less) for both HIV-
infected and control groups. There were no significant dif-
ferences in the percentage of CD8+ T cells expressing CD5
between responses to the different peptides, despite TCR
avidities ranging from 1.0-500 nM. There was also no sig-
nificant difference between the HIV-infected and control
groups for the three non-HIV viral peptides, either indi-
vidually or in unison. However, in both the HIV-infected
and control groups, the median percentage of CD5-
negative CD8+ T cells responding to stimulation with a
low TCR avidity (2.0 μM) self peptide was significantly
higher than it was for the three peptides from common vi-
ruses. Although the four HIV peptides used for these stud-
ies had TCR avidities comparable to, or higher than the
three non-HIV viral peptides, the median percentage of
CD5-negative CD8+ T cells responding to stimulation with
the HIV peptides was also significantly higher, and similar
to the CD8+ T cell responses against the low avidity self
peptide. This was not related to HIV infection itself as
responses against non-HIV viral peptides were similar to
uninfected controls in terms of the percentage of CD5-
negative CD8+ T cells and the percentage of the general
CD8+ T cell population of HIV-infected individuals ex-
pressing CD5 was significantly higher than in the CD8+ T
cell responses against either the HIV peptides or self
Table 2 General characteristics of HIV-infected study subjects
ID Age (years) Sex Duration of HIV infection (years) CD4+ T cells/μL peripheral blood Virus loada Treatmentb
11 44 Female >20 200 2.81 cART
12 40 Male >20 518 <1.6 cART
18 37 Male >20 729 1.97 cART
28 45 Male >20 144 4.94 None
30 50 Male >20 884 <1.6 cART
34 37 Female >20 450 3.26 cART
35 52 Male >25 882 1.6 cART
39 38 Female >20 506 2.74 cART
43 49 Male >20 450 4.15 None
45 42 Female >20 456 <1.6 cART
62 38 Female >20 720 <1.6 cART
65 54 Female >20 306 <1.6 cART
71 38 Female >20 860 <1.6 cART
78 41 Male >20 150 2.73 cART
90 42 Female >10 315 <1.6 cART
92 36 Female >15 325 5.5 None
96 44 Female >15 812 <1.6 cART
105 46 Male >10 527 2.15 cART
115 44 Female >10 704 <1.6 cART
117 45 Male >15 322 <1.6 cART
125 51 Male >10 420 <1.6 cART
126 50 Male >10 754 <1.6 cART
132 37 Female >15 30 5.53 None
134 44 Female >20 780 <1.6 cART
151 54 Male >10 360 <1.6 cART
154 47 Male >20 442 <1.6 cART
155 41 Female >5 500 <1.6 cART
179 44 Male >5 984 <1.6 cART
181 39 Male >20 104 4.79 None
193 43 Female >5 420 <1.6 cART
196 54 Male >5 273 <1.6 cART
197 59 Male >5 616 <1.6 cART
201 52 Male >5 434 <1.6 cART
204 42 Female >20 437 <1.6 cART
213 55 Female >5 561 <1.6 cART
aVirus load is expressed in log10 copies HIV RNA/ml plasma.
bCombination antiretroviral therapy (cART) represents various two or three class highly active antiretroviral drug regimens.
Penney et al. AIDS Research and Therapy 2014, 11:30 Page 6 of 10
http://www.aidsrestherapy.com/content/11/1/30peptide. These data suggest that a general relationship
between the percentage of CD5-negative CD8+ T cells
responding against a peptide and TCR avidity may be
apparent in responses against very low avidity self pep-
tides, but not across a relatively broad range of avidities
associated with peptides from three common viruses
with low mutation rates compared to HIV. In contrast,
the percentage of CD5-negative, HIV-specific CD8+ T cellsresponding against HIV peptides was inconsistent with
their TCR avidities relative to the other viral peptides and
similar to that seen in responses against the low avidity
self peptide.
While CD8+ T cell responses to only a few peptides
and viruses in the context of just one HLA-restriction
molecule (HLA-A2) were studied, we speculate that this
apparent inconsistency in CD5 expression levels could
Figure 4 The percentage of HIV peptide-specific CD8+ T cells expressing CD5 and comparison to other virus peptide and self-peptide-
specific CD8+ T cells. (a) Solid columns represent median values for each individual peptide (identified below the column) with error bars
showing interquartile range and n within each column indicating the number of individuals with specific proliferation against each individual
peptide. (b) Box and whisker plots showing median percentages of non-HIV viral peptide, HIV peptide and self peptide-specific CD8+ T cells
expressing CD5 for healthy controls (grey boxes) and HIV-infected individuals (white boxes). Horizontal lines within the box represent the median,
with boxes illustrating interquartile range and vertical error bars indicating overall range. Significant differences between medians are shown by
p values above lines bracketing the relevant groups (Mann–Whitney test).
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within viral quasispecies. The sequence of wild-type or
reference peptides used for in vitro stimulation is actu-
ally based on a consensus drawn from multiple variants.
Sequence variation generated in vivo probably goes well
beyond that observed in the viruses that successfully
achieve some level of prominence. Thus, for each HIV
peptide epitope defined by a reported consensus se-
quence, the CD8+ T cells of an infected individual are
most likely exposed to multiple variants in vivo, many of
which will continue to be presented by the relevantFigure 5 Proliferative responses against IP-30 self peptide in
healthy controls and HIV-infected individuals. The percentage of
CD8+ T cells proliferating in response to the IP-30 self peptide is
shown for each of 4/24 healthy controls and 13/36 HIV-infected
individuals with positive proliferative responses to the self peptide.HLA class I molecule. Rather than a single TCR/MHC
peptide interaction with a unique associated avidity, this
would produce a spectrum of interactions and avidities
imposing different constraints on CD5 expression levels
compatible with T cell activation. In vivo adaptation to
the many variants producing a generally lower and indi-
vidually more variable percentage of CD5-expressing
CD8+ T cells responding to the wild-type peptide in vitro
is one possible explanation for the results observed in our
study.
Such in vivo adaptation in the percentage of respond-
ing cells expressing CD5 could have positive and nega-
tive implications. Cells lacking CD5 would be selectively
activated and mediate broader recognition of variant
peptides arising in vivo than their CD5 expressing coun-
terparts. However, transgenic TCR studies suggest the
CD5-negative CD8+ T cells would also be more likely to
mediate autoimmunity by reacting against self-peptides
with low avidity TCR interactions and to skew the T cell
repertoire through a selective advantage for homeostatic
proliferation [12,13,16]. This feature might underlie the
more substantial fractional expansion of CD5-negative
CD8+ T cells reported in HIV-infected individuals in the
study carried out prior to the introduction of HAART
[18]. In secondary haemophagocytic lymphohistiocytosis,
often driven by EBV infection, there is a rapid and pro-
found oligoclonal expansion of activated CD5-negative T
cells expressing EBV RNA [22,23]. The oligoclonality of
the CD5-negative cells suggests they may be involved in
the immune response against EBV and that down-
regulation of CD5 facilitates their rapid expansion. This
may facilitate rapid generation of a massive oligoclonal
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relatively stable DNA virus like EBV. In this case, down-
regulation of CD5 could be an effective antiviral adapta-
tion to amplify the immune response, with only a transient
effect on the CD8+ T cell population due to heightened
sensitivity of CD5-negative CD8+ T cells to apoptosis [24].
In this scenario, down-regulation of CD5 could also be ad-
vantageous for tumour infiltrating lymphocytes. However,
the association between EBV infection and CD5 down-
regulation could actually reflect direct infection of the
CD8+ T cells with EBV rather than the immune response
against EBV [22,23].
Adaptive regulation of CD5 expression on T cells may
amplify the immune response in certain settings and
conversely, activate Treg cells in others [25]. The Ets
family E47 transcription factor and IL-7 negatively regu-
late CD5 expression through poorly understood mecha-
nisms [12,26,27]. Better understanding of the impact,
molecular basis and dynamics of CD5 regulation on dif-
ferent T cell subsets could reveal new methods to modu-
late immunity in pathological settings.
Conclusions
There is a general relationship between a reduced per-
centage of responding CD8+ T cells expressing CD5 and
reactivity against the common HLA-A2-restricted low
avidity self peptide used in this study. While this rela-
tionship was not seen across a set of common viral pep-
tides spanning a 500 nM range of avidity, we also
observed reduced CD5 expression on CD8+ T cells re-
active against four HIV peptides similar to that seen
with CD8+ T cells responding against the low avidity self
peptide. Since HIV mutates extensively, one possible
explanation is that down-regulation of CD5 on HIV-
specific CD8+ T cells represents in vivo adaptation to
HIV variant peptides with lower avidities than the refer-
ence peptides used to assess reactivity. This adaptation
would have potential for positive consequences in terms
of functional recognition of a broader set of viral vari-
ants, but also for negative consequences related to auto-
reactivity and narrowing of the T cell repertoire.
Methods
Subjects
Healthy controls were recruited from laboratory and
hospital personnel and HIV-1-infected subjects recruited
through the Newfoundland and Labrador Provincial
HIV Clinic in St. John’s, Newfoundland. Ethical approval
for this study was granted by the Newfoundland and
Labrador Health Ethics Research Authority and all par-
ticipants provided written informed consent for blood
collection and immunological studies. Peripheral blood
was obtained by forearm venipuncture into vacutainers
with acid citrate dextrose anticoagulant (Becton Dickinson)and peripheral blood mononuclear cells (PBMC) were
isolated by ficoll-hypaque plus (GE Healthcare) density
gradient centrifugation. Isolated PBMC were washed
and resuspended in lymphocyte medium consisting of
Roswell Park Memorial Institute (RPMI) 1640, 10%
fetal calf serum (FCS), 10 mM HEPES, 2 mM L-glu-
tamine, 100 IU/mL penicillin, 100 μg/mL streptomycin
and 2 × 10−5 M 2-mercaptoethanol (all from Invitro-
gen). The cells were then counted and used directly for
human leukocyte histocompatibility-linked antigen (HLA)
typing with the remaining cells resuspended at 1.0 × 107/
mL in medium with 20% FCS and 10% dimethylsulfoxide
(Sigma) for preservation in liquid N2 until use. All subjects
were typed for class I A and B HLA antigens by serologic
assay as previously described and those expressing HLA-
A2 chosen for further study [28].
Peptide selection
A selection of peptides presented to CD8+ T cells by
HLA-A2 were used in this study, including immunodomi-
nant peptides from common viruses to which most
individuals are exposed: cytomegalovirus (CMV) pp65
495–503 (NLVPMVATV); Epstein-Barr virus (EBV)
BMLF1 280–288 (GLCTLVAML); influenza (flu) A Matrix
55–63 (GILGFVFTL), interferon inducible protein (IP)-30
-11 to −3 (LLDVPTAAV) self-peptide; HIV-1 peptides
commonly recognized by subjects in our cohort; Gag P17
77–85 (SLYNTVATL); Pol reverse transcriptase (RT1) 33–
41 (ALVEICTEM); Pol RT2 179–187 (VIYQYMDDL); Pol
protease (PR) 76–84 (LVGPTPVNI). The TCR avidities of
these peptides reported in the literature span a 3 log range,
which we confirmed with our own reactive samples. Pep-
tides were synthesized and purified to > 95% purity by
EZBiolab.
ELISPOT assays
Twenty-four HLA-A2 healthy control individuals were
tested by interferon-gamma (IFN-γ) ELISPOT for CD8+
T cells specific for the CMV, flu, EBV and IP-30 self
peptides. Multiscreen microtitre plates (Millipore) were
coated overnight at 4°C with 100 μL/well of 7.5 μg/ml
anti-IFN-γ monoclonal antibody (mAb) 1-D1K (MAbtech)
and then washed 3 times with phosphate-buffered saline
(PBS). Duplicate wells were incubated overnight with
200 μL total volume lymphocyte medium containing 4 μg/
mL of either CMV, EBV, flu or IP-30 peptide and 1×105
PBMC from the subject being tested. Cells recovered from
liquid N2 were cultured overnight before counting to
ensure viability. Medium alone served as negative control
and 5 μg/mL phytohemagluttinin (PHA, MP Biomedicals)
as positive control. After overnight (16 hr) incubation,
PBMC were removed from the wells, the plates washed 6
times and 100 μL of 1 μg/mL biotinylated anti-IFN-γ mAb
7-B6-1 (MAbtech) added for 2 h. Plates were washed 6
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streptavidin-alkaline phosphatase (AP) (MAbtech) added
for 1 h. Plates were washed 6 more times and 100 μL/well
chromogenic AP substrate (BioRad) added. After spots de-
veloped (~30 min), plates were washed with tap water to
stop reactions and then air-dried. Spots corresponding to
cytokine-producing T cells were counted on a Cellular
Technology Limited Immunoscan reader. Subjects were
considered to have detectable memory CD8+ T cells
against the relevant peptides when the number of spot
forming cells (sfc) was > 200/106 PBMC after subtraction
of background spots in negative control wells. Thirty-six
HIV-infected subjects expressing HLA-A2 were tested by
ELISPOT as above for CD8+ T cell reactivity with the non-
HIV peptides and with the 4 common HIV-1 peptides also
presented by HLA-A2 and listed above.
Avidity determination
Avidity levels reported in the literature for TCR interac-
tions with the relevant peptide/HLA-A2 complexes were
confirmed as previously described by serial dilution of
the peptides in cell-mediated cytotoxicity assays [21].
Briefly, cytotoxic T cells (CTL) specific for the peptide
were generated by incubating 5 × 106 PBMC from a re-
active subject in a small volume of medium for 1 hr with
100 μM peptide and then culturing the cells at 2.5 ×
106/mL in medium supplemented with 25 ng/mL re-
combinant interleukin-7 (R&D Systems). After 3 days,
interleukin-2 (Roche) was added to 10 U/mL and the
cells expanded for a further 7 days. The effector cells
were first tested against autologous or HLA-A2 matched
51Cr-labelled BLCL pulsed for 1 hr with 10 μM peptide as
in reference [20] to determine an appropriate effector-to-
target (E:T) ratio and then were tested against target cells
pulsed with a serial dilutions of the test peptide beginning
at 1 μM and progressing through 5 fold dilutions to < 0.02
nM. The avidity of the TCR/peptide-Class I HLA complex
interaction was determined by graphing percent specific
cytotoxicity against peptide concentration and estimating
the concentration of peptide at which specific cytotoxicity
fell to 50% of maximum cytotoxicity observed.
Proliferation assays
To evaluate CD5 expression on peptide-specific CD8+ T
cells, 2×106 PBMC were labeled with 1 μM carboxyfluo-
rescein succinimidyl ester (CFSE, Invitrogen) as per the
manufacturer’s instructions, washed, and incubated in a
small volume with either lymphocyte medium alone or
100 μM peptide of interest for 1 hour, then resuspended
and cultured in 1 mL lymphocyte medium (with human
serum substituted for FCS) for 7 days. Peptide-specific T
cells were identified by CFSE fluorescence intensity dilu-
tion using a Becton Dickinson FacsScan flow cytometer.
CD8+CD3+ cells were identified using phycoerythrin(PE)-conjugated anti-CD3 and peridinyl chlorophyll pro-
tein (PerCP)-conjugated anti-CD8 (clones UCHT1 and
HIT8a respectively, BioLegend). The fraction of prolifer-
ating cells expressing CD5 was estimated by co-staining
the cells with allophycocyanin-conjugated anti-CD5
(clone L17F12, eBioscience), gating on CD8+CD3+ cells
and plotting CD5 versus CFSE intensity. Positive peptide-
specific proliferation was defined as at least twice the per-
centage of proliferating cells compared to the control
culture. If background proliferation in the absence of
stimulation was > 2.5%, results were excluded. The base-
line fraction of CD8+ T cells expressing CD5 was mea-
sured by flow cytometry with fresh PBMC using the same
antibodies.
Statistical analysis
Data analysis and graphical representation was done
with GraphPad Prism software, v4.03. Normality of data
distribution was assessed by Kolmogorov-Smirnoff and
D’Agostino Pearson tests, but medians with interquartile
range were shown since not all data sets in any of the
comparisons had normal distributions. Differences in
the median percentages of different CD8+ T cell popula-
tions expressing CD5 were assessed with the two tailed
non-parametric Mann–Whitney test.
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